Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Plain-language summary
This trial is testing CAR-T cell therapy (genetically modified immune cells) for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 2 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Anti-CD19/CD20/CD22 CAR T-Cells (BIOLOGICAL): Given IV | Cyclophosphamide (DRUG): Given IV | Fludarabine Phosphate (DRUG): Given IV | Echocardiography (PROCEDURE): Undergo echocardiography | Multigated Acquisition Scan (PROCEDURE): Undergo MUGA scan | Biopsy (PROCEDURE): Undergo tissue biopsy | Pheresis (PROCEDURE): Undergo apheresis | Bone Marrow Aspiration and Biopsy (PROCEDURE): Undergo bone marrow aspiration and biopsy | Biospecimen Collection (PROCEDURE): Undergo blood sample collection
Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan, Biopsy, Pheresis, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details